Market Overview

UPDATE: Credit Suisse Lowers PT on Arena Pharmaceuticals Following Management Meeting

Share:
Related ARNA
Arena Pharma Could Be Developing Several Best-In-Class Agents
15 Biggest Mid-Day Gainers For Friday

In a report published Monday, Credit Suisse analyst Lee Kalowski reiterated an Underperform rating on Arena Pharmaceuticals (NASDAQ: ARNA), but lowered the price target from $5.00 to $4.00.

In the report, Credit Suisse noted, “As Q3 closes and following a Friday meeting with management, we are lowering our Belviq US net sales estimate for Q3, Q4, and each year through 2018 (2019-2020 are unchanged). We expect consensus will be coming down in the weeks ahead. We think a capital raise may potentially be required next year and have built this into our model. With these changes, our DCF-derived target price goes from $5 to $4.”

Arena Pharmaceuticals closed on Friday at $5.79.

Latest Ratings for ARNA

DateFirmActionFromTo
May 2017Leerink SwannInitiates Coverage OnOutperform
Sep 2016FBR CapitalInitiates Coverage onOutperform
Nov 2013WallachbethInitiates Coverage onBuy

View More Analyst Ratings for ARNA
View the Latest Analyst Ratings

Posted-In: Credit Suisse Lee KalowskiAnalyst Color Price Target Analyst Ratings

 

Related Articles (ARNA)

View Comments and Join the Discussion!